SI-BONE, Inc. (SIBN) is a Medical - Devices company in the Healthcare sector, currently trading at $14.43. It has a SharesGrow Score of 59/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Analyst consensus target is SIBN = $25 (+75% upside).
Valuation: SIBN trades at a trailing Price-to-Earnings (P/E) of -30.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.3.
Financials: revenue is $201M, +23.7%/yr average growth. Net income is $19M (loss), growing at +32.9%/yr. Net profit margin is -9.4% (negative). Gross margin is 79.6% (-5.6 pp trend).
Balance sheet: total debt is $1M against $178M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 8.55 (strong liquidity). Debt-to-assets is 0.5%. Total assets: $239M.
Analyst outlook: 9 / 9 analysts rate SIBN as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 88/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 49/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).
